TS
Tsumura & Co.
TSMRF · OTC
$23.20 +0.00% (+$0.00)
Market Cap ¥270.1B
P/E Ratio 8.91x
Div. Yield 4.12%
ROE 9.72%
Bulios Fair Price
$18.85
18.7% downside
Current Price
$23.2
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TSMRF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
99 /100
Cheap P/E 8.91x
P/B 0.83x
EV/EBITDA 6.10x
Growth
82 /100
Growing EPS growth 20.65%
Book val. growth 8.70%
Rev. growth 11.44%
Profitability
59 /100
Moderate Gross margin 46.99%
FCF margin 9.35%
Net margin 15.17%
Quality
35 /100
Average ROIC 4.81%
Asset turnover 0.33x
ROE 9.72%
Debt
89 /100
Low Debt/Equity 0.45x
Net debt/EBITDA 1.26x
Current ratio 3.55x
Stability
53 /100
Moderate Beta 0.07x
Profitable years 6
Rev. volatility 7.33%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TSMRF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Terukazu Kato
Employees
4,923
Headquarters
Tokyo
Upcoming events
29 SEP
Ex-Dividend
Ex-dividend date
29 SEP
Dividend Payment
Payment date
09 NOV
Earnings
Upcoming earnings report
30 MAR
Ex-Dividend
Ex-dividend date
30 MAR
Dividend Payment
Payment date